… In this prespecified analysis of the DAPA-CKD trial, we showed that dapagliflozin reduced
albuminuria in patients with chronic kidney disease with and without type 2 diabetes, with a …

… DAPA-CKD is a randomized, double-blind, placebo-controlled, trial in which ∼4300 patients
with CKD Stages 2–4 and elevated urinary albumin excretion will be enrolled. The vast …

… rate (eGFR), and by the level of urinary albumin excretion. Both of these methods of assessing
… of the DAPA-CKD trial along with the DAPA-HF and EMPEROR-reduced trials, SGLT2 …

… Added value of this study In this prespecified analyses of the DAPA-CKD trial, we assessed
the effect of dapagliflozin … Effect of dapagliflozin on urinary albumin excretion in patients with …

… this study included a small subgroup of DAPA-CKD participants and that the number of
events was also small, no prior trial of any therapeutic agent in IgA nephropathy … for DAPA-CKD …

… By including patients with and without type 2 diabetes in the DAPA-CKD trial, we were
able to explore the effects of SGLT2 inhibitors in patients with chronic kidney disease due to a …

… a randomized open-label crossover trial in patients with urinary albumin excretion ≥100
mg/… that recruited patients with type 2 diabetes and CKD. The DAPA-CKD trial confirmed and …

… Prespecified exploratory outcomes were change from baseline in 24-h urinary glucose
excretion, 24-h urinary albumin excretion, LDL cholesterol, HDL cholesterol, uric acid, haematocrit…

… DAPA-HF trials, we now have evidence that SGLT2 inhibition appears safe and efficacious in
patients with moderate (stage 3) CKD… The DAPA-HF trial showed that in patients with HFrEF…

… of dapagliflozin on albumin excretion has been reported [4]. … not controlled for in this study.
Baseline characteristics were … BP, for dapagliflozin (DAPA) 10 mg, DAPA 5 mg and PBO, over …